BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics (OTCQB: BCLI) reported Q2 2026 results for the quarter ended June 30, 2026. It said it is preparing to start the Phase 3b ENDURANCE study of NurOwn in ALS under an FDA-agreed Special Protocol Assessment, planning about 200 patients. Cash was about $0.2M vs $1.03M a year earlier, with Q2 net loss about $3.9M. The company appointed Peter J. Pitts as Executive Chairman and raised about $400k in private placements.

Original reporting
Published Aug 14, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 9:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update — source image
Decision brief

The 30-second read

$BCLINeutralMed
01

Why it matters

The article combines (1) operational readiness claims for ENDURANCE enrollment under SPA, (2) an executive leadership change aimed at regulatory and partnership execution, and (3) updated financials showing a sharp cash decline and higher operating costs.

02

Market read

Traders may reprice near-term probability of ENDURANCE launch and the financing/dilution risk implied by the reduced cash balance.

03

What to watch

The release does not provide enrollment start timing, trial site readiness, or any new financing amount beyond small private placements, leaving execution and funding uncertainty largely unresolved.

Relevance 7/10Novelty 6/10Timing: after-hours release today, Q2 results and corporate update

Background

BrainStorm Cell Therapeutics is advancing NurOwn (MSC-NTF) for ALS and is preparing to initiate a Phase 3b ENDURANCE study under an FDA Special Protocol Assessment.

Company-level read

Ticker impact

$BCLINeutralMedium confidence
Context

BrainStorm reports Q2 2026 cash of about $0.2M and says it is completing work to open the Phase 3b ENDURANCE NurOwn enrollment under FDA SPA.

Expected impact

Likely modest positive bias on SPA readiness and leadership credibility, offset by weak cash balance and higher dilution risk.

Evidence & confidence

The release provides concrete operational milestones (ENDURANCE readiness, SPA) and new financial datapoints (cash down sharply, higher G&A), which can shift probability-weighted timelines and financing expectations.

Market effects

Highlights continued FDA SPA use in ALS cell-therapy development, reinforcing a regulatory pathway narrative for regenerative medicine peers.

Limited, OTC microcap-specific sentiment spillover to small-cap biotech investors.

Low; primarily US regulatory and ALS program execution.

Counterpoint

SPA and leadership appointments may not reduce the core bottleneck: the company still has very limited cash, so dilution or delays could dominate near-term outcomes.

Key entities

  • BrainStorm Cell Therapeutics Inc.

    OTCQB-listed developer of NurOwn adult stem cell therapeutics for ALS.

  • NurOwn (MSC-NTF)

    Autologous MSC-derived neurotrophic factor-secreting cell therapy in ALS Phase 3b ENDURANCE preparation.

  • FDA Special Protocol Assessment (SPA)

    FDA-agreed protocol framework intended to support a future BLA for ENDURANCE.

  • Peter J. Pitts

    Appointed Executive Chairman to lead regulatory, operational, partnership, and capital-markets initiatives.

Related articles

$BCLIMed

BRAINSTORM CELL THERAPEUTICS INC. (BCLI): Notice of Pendency and Proposed Settlement of Stockholder

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK IN RE BRAINSTORM CELL Lead Case No. 1:24-cv-01095-DEH THERAPEUTICS, INC. DERIVATIVE LITIGATION EXHIBIT C NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF STOCKHOLDER DERIVATIVE MATTERS TO: ALL RECORD HOLDERS AND

$BCLIMed

BrainStorm Cell Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BrainStorm Cell Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update NEW YORK, November 16, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegener

$BCLIMed

BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update NEW YORK, Aug 14, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerativ

$ORCLMed

Oracle says OpenAI contract is fully funded, addresses market financing scrutiny

Oracle (NYSE:ORCL) announced it has fully funded its cloud infrastructure contract with OpenAI, completing a $20B capital raise plan. The company addressed market scrutiny over financing, reiterating its commitment to positive free cash flow by H2 2028 and $30B annual free cash flow by 2029. Oracle also updated progress on its data center buildout, including sites for OpenAI's AI models.

$FMed

Ford launches Super Dutys at Oakville, a boon for tariff-hit Canada

Ford Motor Co. has resumed F-Series Super Duty truck production at its Oakville Assembly Complex in Canada, following a $3.5 billion investment. The move aims to meet demand, reduce wait times, and support Canada's automotive industry amid tariffs and plant closures by competitors. The Canadian government and Ontario province contributed $324 million and $206 million, respectively.